These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2563211)

  • 1. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alprazolam augmentation of neuroleptics in schizophrenia.
    Wolkowitz OM; Breier A; Doran A; Lucas P; Kelsoe J; Paul SM; Pickar D
    Am J Psychiatry; 1989 Aug; 146(8):1087-8. PubMed ID: 2568762
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.
    Barbee JG; Mancuso DM; Freed CR; Todorov AA
    Am J Psychiatry; 1992 Apr; 149(4):506-10. PubMed ID: 1348161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
    Wolkowitz OM; Breier A; Doran A; Kelsoe J; Lucas P; Paul SM; Pickar D
    Arch Gen Psychiatry; 1988 Jul; 45(7):664-71. PubMed ID: 3289524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alprazolam augmentation of antipsychotic pharmacotherapy?
    Thienhaus OJ; Somoza E; Nobilski M
    Arch Gen Psychiatry; 1989 Nov; 46(11):1052-3. PubMed ID: 2818141
    [No Abstract]   [Full Text] [Related]  

  • 8. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
    Krakowski M; Czobor P; Volavka J
    Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of positive and negative symptoms: pharmacologic approaches.
    Boyer P; Lecrubier Y; Puech AJ
    Mod Probl Pharmacopsychiatry; 1990; 24():152-74. PubMed ID: 1970852
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alprazolam and neuroleptic drug in treating schizophrenia.
    Bacher NM; Lewis HA; Field PB
    Am J Psychiatry; 1986 Oct; 143(10):1311-3. PubMed ID: 2876649
    [No Abstract]   [Full Text] [Related]  

  • 19. Alprazolam-neuroleptic combination in schizophrenia.
    Lipinski JF; Cohen BM
    Am J Psychiatry; 1986 Nov; 143(11):1501-2. PubMed ID: 2877587
    [No Abstract]   [Full Text] [Related]  

  • 20. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.